Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
Phase: PHASE4
Conditions: Type 2 Diabetes Mellitus (T2DM)
Sponsor: Novartis Pharmaceuticals

Novartis Pharma LLC, Russia 
Interventional Study Protocol 
CLAF237ARU05 / NCT02670928 
Interventional study of active weight management in patients with 
type 2 diabetes and obesity in routine clinical practice during 12 
months 
Authors: 
 
Document type: 
Interventional Study Protocol  
Version number: 
4 (with incorporated Amendment 1)  
Release date: 
29-July-2015
English translation 
date: 
26.11.15 
Property of Novartis 
Confidential 
May not be used, divulged, published, or otherwise disclosed 
without the consent of Novartis 

Novartis 
Confidential 
Page 2 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Table of contents 
Table of contents ................................................................................................................. 2 
1 
List of abbreviations ............................................................................................................ 4 
2 
Responsible parties .............................................................................................................. 5 
3 
Glossary of terms ................................................................................................................. 6 
4 
Protocol synopsis ................................................................................................................. 7 
Changes in Protocol ............................................................................................................. 9 
5 
Introduction ....................................................................................................................... 10 
5.1 
Background ............................................................................................................ 10 
5.2 
Purpose .................................................................................................................. 10 
6 
Study objectives ................................................................................................................. 11 
6.1 
Primary objective(s)............................................................................................... 11 
6.2 
Secondary objectives ............................................................................................. 11 
6.3 
Primary end point .................................................................................................. 11 
6.4 
Secondary end points ............................................................................................. 11 
7 
Investigational plan ........................................................................................................... 12 
7.1 
Study design .......................................................................................................... 12 
*All indicators are collected the same way as in active group (see the table 7-1 as a 
reference). Acceptable deviation from the planned date for visits is  +/- 3 
days. ....................................................................................................................... 15 
7.2 
Rationale of study design ...................................................................................... 15 
7.3 
Rationale of dose/regimen, route of administration and duration of treatment ..... 16 
7.4 
Rationale for choice of comparator ....................................................................... 16 
7.5 
Purpose and timing of interim analyses/design adaptations .................................. 16 
7.6 
Risks and benefits .................................................................................................. 16 
8 
Population .......................................................................................................................... 16 
8.1 
Inclusion criteria .................................................................................................... 17 
8.2 
Exclusion criteria ................................................................................................... 17 
9 
Treatment ........................................................................................................................... 18 
10 Visit schedule and assessments ......................................................................................... 18 
10.1 
Withdrawal of Consent form ................................................................................. 21 
10.1.1 
Early study termination ......................................................................... 21 
10.2 
Information to be collected on screening failures .................................................. 21 
10.3 
Patient demographics/other baseline characteristics ............................................. 21 
10.4 
Safety ..................................................................................................................... 21 
10.4.1 Physical examination .................................................................................. 22 

Novartis 
Confidential 
Page 3 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
10.4.3 
Height, weight, body mass index, waist circumference, waist/hip 
ratio ....................................................................................................... 22 
10.4.4 
Laboratory evaluations .......................................................................... 23 
10.4.4.5 Electrocardiogram (ECG) ........................................................................ 23 
10.4.5 
Appropriateness of safety measurements .............................................. 23 
10.5 
Other assessments .................................................................................................. 23 
10.5.1 
Health economic supply form ............................................................... 23 
10.5.2 
Hypoglycemia Perspectives Questionnaire ........................................... 24 
11 Safety monitoring .............................................................................................................. 24 
Serious Adverse Events (SAEs) ............................................................................ 25 
Notification of serious adverse events to Novartis Pharmaceuticals Drug Safety & 
Epidemiology (DS&E) .......................................................................................... 26 
12 Data review and database management ............................................................................. 27 
12.1 
Site monitoring ...................................................................................................... 27 
12.2 
Data collection ....................................................................................................... 28 
12.3 
Database management and quality control ............................................................ 28 
13 Data analysis ...................................................................................................................... 28 
13.1 
Sample size calculations ........................................................................................ 29 
14 Ethical considerations ........................................................................................................ 29 
14.1 
Council of Ethics ................................................................................................... 29 
14.2 
Ethical support of the study ................................................................................... 29 
14.3 
Patient Informed Consent ...................................................................................... 29 
14.4 
Confidentiality of the personal data of the patients ............................................... 30 
14.5 
Regulatory and ethical compliance ........................................................................ 30 
14.6 
Informed consent procedures ................................................................................. 30 
14.7 
Responsibilities of the investigator and IRB/IEC .................................................. 31 
14.8 
Publication of study protocol and results............................................................... 31 
15 Protocol adherence ............................................................................................................ 31 
16 Protocol Amendments ....................................................................................................... 31 
17 References ......................................................................................................................... 32 
 

Novartis 
Confidential 
Page 4 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
1 
List of abbreviations 
AE 
Adverse Event 
BMI 
Body Mass Index 
BP 
Blood pressure 
CAD 
Coronary artery disease 
CI 
Confidence interval 
CRF 
Case Record Form 
DBP 
Diastolic blood pressure 
DM 
Diabetes mellitus 
ECG 
Electrocardiography 
eCRF  
Electronic Case Record Form 
FPG 
Fasting plasma glucose 
HbA1c 
Glycosylated hemoglobin 
hCG 
Human chorionic gonadotropin 
HDL 
High Density Lipoprotein 
HE 
Health economic 
LDL 
Low Density Lipoprotein 
LEC 
Local Ethic Committee  
PhA 
Physical activity 
PPG 
Postprandial Glucose 
RAE 
Russian Association of Endocrinologists 
QoL 
Quality of Life 
SAE 
Serious Adverse Event 
SBP 
Systolic blood pressure 
T2DM 
Type 2 Diabetes mellitus 
TE 
Therapeutic exercise 
TG 
Triglycerides 
 

Novartis 
Confidential 
Page 5 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
2 
Responsible parties 
Table 2-1. Main responsible parties 
Role 
Person 
 
Main protocol author 
 
 
 
 
Principal investigator (PI) 
 
 
 
Scientific support 
 
 
 
Medical Safety Expert 
 
 
 
 
 

Novartis 
Confidential 
Page 6 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
3 
Glossary of terms 
Assessment 
A procedure used to generate data required by the study 
Cohort  
A group of newly enrolled patients treated at a specific dose and regimen 
(i.e. treatment group) at the same time 
Enrollment 
Point/time of patient entry into the study at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in 
the protocol) 
Protocol 
A written account of all the procedures to be followed in a trial, which 
describes all the administrative, documentation, analytical and clinical 
processes used in the trial. 
Part  
A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients with 
established disease and in those with newly-diagnosed disease. 
Period 
A subdivision of a cross-over study 
Premature subject/patient 
withdrawal 
Point/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; at 
this time all study treatment administration is discontinued and no 
further assessments are planned, unless the patient will be followed for 
progression and/or survival 
Study discontinuation 
Point/time when patient permanently stops taking study/investigational 
treatment  for any reason; may or may not also be the point/time of 
premature patient withdrawal 
Subject Number  
A number assigned to each patient who enrolls into the study  
Variable 
A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study 

Novartis 
Confidential 
Page 7 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
4 
Protocol synopsis 
Protocol number 
 
Title 
Interventional study of active weight management in 
patients with type 2 diabetes and obesity in routine 
clinical practice during 12 months 
Brief title 
Feeling better together 
Sponsor 
Novartis 
Investigation type 
Non drug 
Study type 
Interventional study 
Purpose and rationale 
This study is aimed to achieve of long-term weight 
loss in T2DM patients by use of comprehensive 
lifestyle changes program, providing patients with 
structured diet, exercise plan, group behavioral support 
and group education. Additionally the study is 
designed to establish reduction of the body weight 
leads to the improvement of glycemic and lipid 
metabolism, and can also reduce blood pressure level.  
The study is also directed to show that lifestyle 
changes program in T2DM patients can lead to 
decreasing of hospitalization rate and healthcare 
consumption. In order to demonstrate a change from 
standard of care, data will be collected from a parallel 
cohort from the same centers. 
Primary Objective(s) and Key Secondary Objective 
The primary objective of the study is to demonstrate 
that comprehensive lifestyle changes program  for 
patients with T2DM can lead to clinically significant 
weight reduction (>5%)  compared with baseline in 12 
months of observation. 
Secondary Objectives 
The secondary objective is to show that intensive 
lifestyle changes program for patients with T2DM can 
lead to: 
• 
weight reduction compared with baseline in 3, 6, 9 
months of observation 
• 
improved glycemic control: HbA1c and FPG 
• 
improved blood pressure level 
• 
improved lipid profile  
• 
improved QoL 
Study design 
This is a interventional, multicenter, non-randomized, 
parallel-group, opened designed study lasting during 
12 months for approximately 130 patients with type 2 
diabetes and obesity. 
Population 
The study is expected to include approximately 100 
patients with T2DM and obesity who will be on active 
management and another 30 patients whose case 
records will be collected from routine clinical practice 
for comparison purposes.  
Inclusion 
criteria 
• 
Signed Informed Consent. Written informed 
consent must be obtained before any assessment is 

Novartis 
Confidential 
Page 8 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
performed. 
• 
≥ 18 years 
• 
Type 2 diabetes 
• 
The Body Mass Index is from 28 to 40 kg/m2 
Exclusion criteria 
• 
Pregnant or nursing (lactating) women, where 
pregnancy is defined as the state of a female after 
conception and until the termination of gestation. 
• 
Type 1 diabetes 
• 
Proliferative retinopathy 
• 
Renal impairment: serum creatinine >1.5 mg/dL, 
creatinine clearance < 40 ml/min and/or 
proteinuria 
• 
The lack of ability to perform the physical 
exercises due to the orthopedic or cardiovascular 
disorders 
• 
Chronic alcoholism, acute alcoholic intoxication 
Investigational and reference therapy 
No drugs will be supplied during the study. 
Hypoglycemic drug therapy will be provided 
according routine standard practice without any special 
changes.  
Efficacy assessments 
• 
Weight reduction 
• 
Control of glycemic in HbA1C and FPG 
• 
Blood pressure 
• 
Lipid profile indicators 
Safety assessments 
• Adverse events 
• Vital signs 
• Laboratory assessments  
• ECG 
Other assessments 
• HE supply form  
• Survey for hypoglycemic assessment 
• Scale of individual perception of physical exercises 
(Borg scale) 
Data analysis 
Descriptive statistics will be applied in the study to 
describe the sample size of the patients at baseline and 
at follow-up visits, demographic data recorded during 
the examination of the study parameters, as well as 
their changes. 
The primary analysis of the proportion of the patients 
with response on the treatment will be performed using 
multivariate logistic regression and calculating odds 
ratios with corresponding 95% CI. To control the 
potential confounding factors, age, sex, BMI, disease 
duration, the baseline values of HbA1c will be taken 
into account in the regression model. 
Key words 
Type 2 Diabetes mellitus, obesity, life changes 

Novartis 
Confidential 
Page 9 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Amendment 1 
Changes in Protocol 
Changes in Protocol are indicated in track changes in the following mode: deleted paragraphs 
are marked as text deleted, new paragraphs are marked in bold. 
Background for the Addendum. 
This Addendum is made to optimize the schedule of tests and visits for patients, i.e.: 
• Results of physical examinations, indications of BMI, waist circumference and 
waist/hip circumference ratio in patients of active groups in the first three months will 
be registered in four and eight weeks after inclusion into the study. 
• Analysis of HbA1c will be conducted at the Visit 1 and then after 12, 24, 36 and 48 
weeks after the patient is included in the study. 
• Complete blood count and biochemical blood tests, general urine test and ECG will be 
conducted at Visit 1 and then after 12 and 48 weeks after the patient is included in the 
study. 
• HE supply form will be conducted at the 1st visit and then at the end of study (week 
48). 
Another changes/corrections were made to ensure the text is cohesive and consistent and is 
stylistically viable. 
 
Approval by the Independent Ethical Committee 
Before this Protocol version with incorporated Addendum 1 becomes active it should be 
verified and approved by the Independent Ethical Committee. Additionally, above mentioned 
changes also relate to the Consent form that should also be approved by the Research centers. 
Signed Certificate should be at Sponsor’s disposal once approved by the Independent Ethical 
Committee. 
Summary of the previous Addendums 
Not applicable. 
 
 

Novartis 
Confidential 
Page 10 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
5 
Introduction 
5.1 
Background  
Type 2 Diabetes mellitus (T2DM) is a chronic, progressive disease characterized by 
hyperglycemia due to multiple metabolic disorders, including the resistance of peripheral 
tissues to insulin, inappropriate secretion of insulin, increased glucose production in the liver 
and hyperglucagonemia [1]. 
Most part of the patients with T2DM has obesity. Global data indicates that 80% of patients 
with diabetes mellitus are overweight, and in patients with type 2 diabetes, this proportion is 
higher. In Russia about 50% of the patients with T2DM are suffering from obesity (body mass 
index [BMI] > 30 kg/m2) and 45% of patients are overweight (BMI 25-29 kg/m2). In the 
process of body weight management in patients with T2DM, there are certain problems: 
unwillingness of the physicians and the patients to modify the lifestyle, the diet and the habits, 
as well as use of the drug (insulin, sulphonylurea) leading to increase in body weight. Surveys 
confirm that one third of the physicians do not give to the patients with obesity any 
recommendations for lifestyle modification in obesity. It indicates that the physicians do not 
have the tools to long-term change of these parameters [2]. 
The adipose tissue is the basis for the development of insulin resistance; therefore, obesity is a 
significant aggravating factor for achievement of the carbohydrate metabolism compensation 
and is associated with cardiovascular risk factors [3]. 
The adipose tissue is the potent endocrine organ synthesizing hormones and adipokines, most 
of which negatively influence on the cardiovascular risk profile (increase in BP, activation of 
pro-inflammatory and pro-thrombotic processes, atherogenic effects) [4]. 
According to the one of the largest studies in the diabetes history - Look AHEAD (follow-up 
for 13.5 years), it was evidenced that in patients with reduced body weight and with the 
maintenance the result in the course of the study, the parameters of the cardiovascular 
diseases and mortality, the incidence of the strokes and heart attacks decreased [5]. 
This study complies with the guidelines for medical care provision for the patients with 
T2DM in the Russian Federation. The algorithms for specialized medical care of patients with 
T2DM [6] recommend as the based therapy the combination of the following approaches: 
• 
 Diet therapy 
• 
 Physical activity 
• 
 Antidiabetic drugs 
• 
 Education and self-control. 
This study provides the personalized approach to the lifestyle changes in the patients, the 
development of an optimal exercise and nutrition plan, the change in the behavioral habits of 
the patient in order to adopt the corrections and to the improve the adaptation, as well as to 
adjust a drug treatment plan in order to use the agents, indifferent to the body weight. 
 
5.2 
Purpose  
This study is aimed to achieve of long-term weight loss in T2DM patients by use of 
comprehensive lifestyle changes study, providing patients with structured diet, exercise plan, 

Novartis 
Confidential 
Page 11 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
group behavioral support and group education. Additionally the study is designed to establish 
that reduction of the body weight leads to the improvement of glycemic and lipid metabolism, 
and can also reduce blood pressure level. The study is also directed to show that lifestyle 
changes study in T2DM patients can lead to decreasing of hospitalization rate and healthcare 
consumption. In order to demonstrate a change from standard of care, data will be collected 
from a parallel cohort from the same centers. 
6 
Study objectives 
6.1 
Primary objective(s) 
The primary objective of the study is to demonstrate that comprehensive lifestyle changes 
program for patients with T2DM can lead to weight reduction compared with baseline in 12 
months of observation. 
6.2 
Secondary objectives 
The secondary objective is to show that intensive lifestyle changes program for patients with 
T2DM can lead to: 
• weight reduction compared with baseline in 3, 6, 9 months of observation 
• improved glycemic control: HbA1c and FPG 
• improved blood pressure level 
• improved lipid profile  
• improved QoL (assessment of changes based on Nvs survey in hypoglycemia and 
scale of individual perception of PhA (scale of Borg) 
• assess changes of another anthropometric indicators (waist circle, proportion of waist 
circle and circle of hips, BMI) 
• HE assessment of drug therapy in patients with T2D in active and control groups. 
 
6.3 
Primary end point 
Number of patients in active and control groups who presented a weight reduction in 12 
months and not less than 5% compared with the baseline. 
6.4 
Secondary end points 
• Weight reduction in % and in absolute numbers compared with baseline in 3rd, 6th, 9th 
and 12th months of observation; 
• Number (proportion) of patients who showed weight reduction not less than 5% 
compared with the baseline in 3rd, 6th, 9th and 12th months of observation; 
• Number (proportion) of patients who showed weight reduction not less than 10% 
compared with the baseline in 3rd, 6th, 9th and 12th months of observation; 

Novartis 
Confidential 
Page 12 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
• Change of HbA1c and FPG in % and absolute numbers; 
• Number (proportion) of patients who reached reduction of HbA1c at least of 0,5% 
compared with the baseline;  
• Number (proportion) of patients who reached reduction of HbA1c of <7% in 12 
months of observation; 
• Change of arterial blood pressure in absolute numbers compared with the baseline; 
• Number (proportion) of patients who reached reduction of SBP and DBP at least at 5 
mm Hg; 
• Change in lipid profile (cholesterol, triglycerides, lipid protein of high and low 
density) compared with the baseline in % and absolute numbers; 
• Change in waist circle, proportion of waist circle and circle of hips; 
• Change in BMI; 
• Assessment of change in hypoglycemia based on Nvs survey for the patients in active 
group – also based on Borg scale (individual perception of PhA). 
 
7 
Investigational plan 
7.1 
Study design 
This is a interventional, multicenter, non-randomized, parallel-group, opened designed study 
lasting during 12 months for approximately 130 patients with type 2 diabetes and obesity.  
In spite of interventional study status, the drug therapy administration is carried out strictly in 
accordance with the approved instructions for medical use, only with the registered 
indications and in accordance with appropriate clinical practice. The decision on the drug 
therapy administration should be based only on the medical indications and on the judgment 
of a physician, but should not be dependent on the decision to include the patient in the study. 
The project includes unique method of weight management, specifically designed for the 
patients with type 2 diabetes. It includes five components: 
1) Structured modified diet change; 
2) Balanced and personalized physical exercises; 
3) Cognitive behavioral support; 
4) Intensive interactive medical assistance; 
5) Group education. 
An outline of the study design is presented in Figure 7-1. The full study lasts 12 months (1 
month constitutes 4 weeks or 28 days). Patients from active group are monitored intensely 
during the first three months (on a weekly basis with acceptable window of visits +/- 1 day) 

Novartis 
Confidential 
Page 13 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
and then maintained on the study for the remaining 9 months. Plan of activities with the step 
of one week is described in the Appendix 1. 
Figure 7-1 
Study design 
  
Information materials will be handed out to patients in active group during the group classes 
(Appendix 8, 9, 10, 11, 12, 13, 1): 
• Diary of self-control 
• Information card 
• Diabetes practicum 
• Practicum on nutrition (Hurmanica) 
• Practicum on physical activity (PhizcultUra) 
• Psychological practicum (fly of bumblebee) 
 
After the first 13 weeks, monthly assessments are made on weight and health status for active 
group. Key biomarkers are measured (Please see Table 6-1) and the physician makes a 
decision on whether the diabetes medicines need to be adjusted as the patient reduces weight.  
Table 7-1. Assessment visit schedule in active group 
Visit 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
Week* 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
Obtain informed 
consent 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion 
criteria 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consultation of 
cardiologist 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consultation of 
ophtalmologist 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypoglycemic therapy 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Concominant therapy 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Consultation of a 
psychologist 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis 
Confidential 
Page 14 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Nutritionist consultaition 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TE doctor/fitness trainer 
consultation 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic data1 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes history2 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relevant medical 
history / current 
medical condition3 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group classes with 
endocrinologist 
 
X 
X 
X 
X 
X 
Х 
X 
Х 
X 
Х 
X 
Х 
 
 
 
 
 
 
 
 
 
Group classes with 
psychologist 
 
X 
X 
X 
X 
X 
Х 
X 
Х 
X 
Х 
X 
Х 
 
 
 
 
 
 
 
 
 
Group classes of 
nutrition 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Х 
 
 
 
 
 
 
 
 
 
Group classes of 
medical physical culture 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Х 
 
 
 
 
 
 
 
 
 
Physical examination 
Х 
 
 
 
 
X 
 
 
 
X 
 
 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
HbA1c 
Х 
 
 
 
 
 
 
 
 
 
 
 
Х 
 
 
Х 
 
 
Х 
 
 
Х 
FPG 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Weight 
Х 
Х 
Х 
Х 
Х 
X 
Х 
Х 
Х 
X 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
BMI 
Х 
 
 
 
Х 
 
 
 
Х 
 
 
 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Waist circumference 
Х 
 
 
 
X 
 
 
 
X 
 
 
 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Waist/hip ratio 
Х 
 
 
 
X 
 
 
 
X 
 
 
 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Blood pressure 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
ECG (standard 12- 
lead) 
Х 
 
 
 
 
 
 
 
 
 
 
 
Х 
 
 
 
 
 
 
 
 
Х 
General blood pressure4 
Х 
 
 
 
 
 
 
 
 
 
 
 
Х 
 
 
 
 
 
 
 
 
Х 
Clinical blood 
chemistry5 
Х 
 
 
 
 
 
 
 
 
 
 
 
Х 
 
 
 
 
 
 
 
 
Х 
Urinalysis6 
Х 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
Х 
AEs 
Х 
Х 
Х 
Х 
Х 
X 
Х 
Х 
Х 
X 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Diaries of self-control 
Х 
Х 
Х 
Х 
Х 
X 
Х 
Х 
Х 
X 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Hypoglycemia 
questionnaires  
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Х 
 
 
 
 
 
Х 
Scale of Borg7 
 
Х 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Х 
HE supply form 
Х 
 
 
 
Х 
 
 
 
Х 
 
 
 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
Х 
                                                 
*Acceptable deviation for weekly planned visits (visits 2-13) is +/-1 day from the planned date, monthly visits 
(visits 14-22) is +/- 3 days from the planned date. 
1 Demographic indicators: age, gender, race. 
2 Date of diagnosis of diabetes, clinical symptoms. 
Therapy for diabetes: insulin (type, dosage), insulin+oral hypoglycemic therapy (type, dosage), sulphonylurea 
(type, dosage), glinide (type, dosage), metformin (dosage), TZD (dosage), DPP4 (type, dosage), GLP1 (type, 
dosage), other type of treatment.  
Complications of diabetes: cardio-vascular diseases, strokes, retinopathy, neuropathy, nephropathy, diabetic foot, 
other.   
3 Concomitant diseases (cardio-vascular diseases, hypertension, eye diseases, vascular diseases of the brain, 
gastrointestinal tract diseases, respiratory diseases, liver and bile ducts diseases, kidney diseases, blood diseases, 
etc.) 
4 General blood test: hemoglobin, leukocytes (+formula), erythrocytes, thrombocytes, ESR. 
5 Clinical blood test: crude protein, cholesterol, lipids of low and high density, triglycerides, ALT, AST, KPhK, 
creatinine, GFR.  
6 Urine analysis: color, transparency, relative density, traces of protein, sugar in urine, ketone bodies. 
7 Scale of Borg (scale of individual perception of physical training) is part of Information card (Appendix 8). 

Novartis 
Confidential 
Page 15 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Study completion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Х 
The parallel group will be examined for all criteria at the beginning of the study and invited 
for physician examination at months 3, 6, 9 and 12 to collect data on primary and secondary 
endpoints (Please see Table 7-2). 
Table 6-2. Assessment visit schedule in control group 
Visit 
1 
2 
3 
4 
5 
Week 
 
12 
24 
36 
48 
Obtain informed 
consent 
Х 
 
 
 
 
Inclusion/exclusion 
criteria 
Х 
 
 
 
 
Hypoglycemic therapy 
Х 
Х 
Х 
Х 
Х 
Concomitant therapy 
Х 
Х 
Х 
Х 
Х 
Endocrinologist 
consultation  
Х 
Х 
Х 
Х 
Х 
Demographic data 
Х 
 
 
 
 
 Diabetes history 
Х 
 
 
 
 
Relevant medical 
history / current 
medical condition 
Х 
 
 
 
 
Physical examination 
Х 
Х 
Х 
Х 
Х 
HbA1c 
Х 
Х 
Х 
Х 
Х 
FPG 
Х 
Х 
Х 
Х 
Х 
Weight 
Х 
Х 
Х 
Х 
Х 
BMI 
Х 
Х 
Х 
Х 
Х 
Waist circumference 
Х 
Х 
Х 
Х 
Х 
Waist/hip ratio 
Х 
Х 
Х 
Х 
Х 
ECG (standard 12- 
lead) 
Х 
Х 
 
 
Х 
General blood test* 
Х 
Х 
 
 
Х 
Clinical 
chemistry* 
Х 
Х 
 
 
Х 
Urinalysis* 
Х 
Х 
 
 
Х 
AEs 
Х 
Х 
Х 
Х 
Х 
Survey on hypoglycemia 
Х 
 
Х 
 
Х 
HE supply form 
Х 
Х 
Х 
Х 
Х 
Study completion  
 
 
 
 
Х 
*All indicators are collected the same way as in active group (see the table 7-1 as a reference). 
Acceptable deviation from the planned date for visits is  +/- 3 days. 
7.2 
Rationale of study design 
This study focuses on a population of patients who present with T2DM and obesity. All 
patients are eligible for both active and parallel groups only in the case of fulfilling all 
inclusion criteria and not fulfilling all exclusion criteria (see chapter 4). Study design is 
aligned with previously published studies of lifestyle changes in such patients [2,5].  
Study is non-randomized. Patients can be included in active or control groups only provided 
they meet all the inclusion and exclusion criteria. By doing this we ensure the effect of 
another influencing factors are minimized. 

Novartis 
Confidential 
Page 16 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Study period and parallel group study design allows achieving of primary end point.  
The control group indicators should be coordinated with the indicators of patients in active 
group. The following should be taken into account when active group is being formed: 
correspondence of BMI and baseline HbA1c. The decision on whether the patient is included 
in active or control group is made by the doctor. 
 
7.3 
Rationale of dose/regimen, route of administration and duration 
of treatment 
Not applicable. 
7.4 
Rationale for choice of comparator 
Not applicable. 
7.5 
Purpose and timing of interim analyses/design adaptations 
No interim analyses will be performed. The primary endpoint analysis will be performed at 
the end of the study, after all patients have completed their study assessments and the database 
locked.  
7.6 
Risks and benefits  
The risk to subjects in this trial will be minimized by compliance with the eligibility criteria 
and study procedures, close clinical monitoring. 
There are no therapy changes or innovations in this study. The drug therapy administration is 
carried out strictly in accordance with the approved instructions for medical use, only with the 
registered indications and in accordance with appropriate clinical practice. 
The study is designed to establish for patients with T2DM and obesity the reduction of the 
body weight, improvement of glycemic and lipid metabolism, and reducing blood pressure 
level.  We expect that the study can improve a QoL and reduce diseases complications in the 
study populations. Nvs survey on hypoglycemia will be used to assess the quality of life in 
patients (Appendix 2).  
8 
Population 
The study is expected to include approximately 100 patients with T2DM and obesity. It is 
planned to have 100 patients in the active group who will be on active life style management; 
the control group will be 30 patients who will be matched with active group in terms of their 
indicators. Both groups will receive standard drug therapy for diabetes.  
The control group should match the active group. The following criteria should be taken into 
account (criteria of inclusion and exclusion): match in BMI (<30; >30) and baseline HbA1c 
(<7.5; >7.5). The decision to include a patient into active or control group should be made by 
a doctor. 

Novartis 
Confidential 
Page 17 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Drop-out of patients is expected for about 20% of patients compared with the originally 
included population. The drop-out criteria is three in a row missed group classes in the first 12 
weeks of the study in active group. 
The drop-out in control group is not expected. 
Patients will be distributed among two participating research centers. 
The study will be executed in two sites, the 
 in Moscow and 
the 
 in Kazan. The adult patients with T2DM (men and 
women at the age of more than 18 years) will be under the observation if they need in the 
active weight loss according to the physician’s decision and if a doctor decides that the active 
approach is necessary. 
An investigator must ensure that the participation in the study will be offered only to the 
patients, which meet the criteria for the study participation. To ensure the representativeness 
of the sample size, an investigator should not use any additional exclusion criteria; in addition, 
he/she must provide equal access to the study participation for all patients suitable for 
inclusion criteria. Drug therapy administration should be based exceptionally on the medical 
indications and should not aim at the inclusion of the patient in the study. 
8.1 
Inclusion criteria 
Patients eligible for inclusion in this study have to fulfill all of the following criteria: 
1. Signed Informed Consent Form (Appendix 3 and 4). Written informed consent must 
be obtained before any assessment is performed. 
2. Signed Informed Consent Form of doctor-ophthalmologist (Appendix 5) and 
cardiologist (Appendix 6) about inclusion of the patient *. 
3. Men and women at the age of 18 years and older 
4. Type 2 diabetes 
5. The Body Mass Index is from 28 to 40 kg/m2 
The objective to have a signed consent form from ophthalmologist and cardiologist is to 
ensure the patient can practice physical exercises and the level of physical activity for a 
patient (active, with limitations and what particular limitations) based on the existing 
condition – if cardio-vascular diseases are present. Consultation of ophthalmologist and 
cardiologist should be conducted before patients are included in the study. Medical specialists 
will be selected from the existing research center staff (Moscow and Kazan) where he study 
will be conducted. 
8.2 
Exclusion criteria 
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients. 
1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a 
female after conception and until the termination of gestation. 

Novartis 
Confidential 
Page 18 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
2. Type 1 diabetes 
3. Proliferative retinopathy, hemorrhage and peeling of a retina. 
4. Renal impairment: serum creatinine >1.5 mg/dL, creatinine clearance < 40 ml/min 
and/or proteinuria 
5. The lack of ability to perform the physical exercises due to the orthopedic or 
cardiovascular disorders* 
6. Chronic alcoholism, acute alcoholic intoxication. 
*The criteria is only applicable to the active group. 
9 
Treatment 
Hypoglycemia drug therapy will be applied to the study participants according to the routine 
clinical practice, no limitations to correct the therapy (for the reason a patient takes part in the 
study) is implied. 
The drug therapy administration is carried out strictly in accordance with the approved 
instructions for medical use, only with the registered indications and in accordance with 
appropriate clinical practice. 
The investigator should inform the patients that in case the patient change their therapy or 
take new drugs the patients should inform the investigator. All drugs (including non-patterned 
name, dosage, first and end date of intake)  and clinically significant non-medical therapy that 
are used by the patients to treat diabetes at the moment the patient enters the trial should be 
registered in eCRF. 
10 
Visit schedule and assessments 
Patients will be subject to a comprehensive evaluation of health and functional status.  
The main parameters, which should be measured in accordance with the periodicity adopted 
in routine practice: 
• 
BMI and body weight 
• 
Waist circumference, ratio between waist and hip 
• 
НвА1с, FPG 
• 
BP (SBP, DBP) 
• 
Lipid profile (cholesterol, triglycerides, LDL, HDL) 
• 
The number of DM related hospitalizations 
• 
QoL data via filling of questionnaires 
• 
HE data (Appendix 7) 
The full study lasts 12 months. Patients in active group are monitored intensely every 7 days. 
After first 13 weeks assessment of weight and health condition are conducted on a monthly 
basis (see Table 7.1 as reference). For patients in control group all examinations should be 
conducted every three months (see Table 7.2 as reference). 

Novartis 
Confidential 
Page 19 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
In order to collect data for the primary and secondary end points (6.3, 6.4) in control group 
assessment of all indicators will be conducted at trial’ start and then the patients will be 
invited to the doctor by the end of 3rd, 6th, 9th and 12th months (see table 7-2). 
Patients from active group fill out the Information card before they enter the study (Appendix 
8) and Registration form (Appendix 9). Patients fill out the Information card at the end of the 
study as well (including assessment of individual perception of physical exercises using the 
scale of Borg). 
It is necessary to discuss with a patient the patient’s ability and readiness to make changes in 
his/her lifestyle when a doctor makes a decision to include a patient in the study. 
The program of active weight reduction includes group classes with the team of doctors: 
• Nutritionist in regards to healthy nutrition (Appendix 10) 
• TE doctor/fitness trainer in regards to physical activity (Appendix 11) 
• Psychologist in regards to motivation and education (Appendix 12) and self-control 
(Appendix 13) 
• Endocrinologist (Appendix 13). 
Classes for the patients in active group are conducted one time a week in the first 12 weeks 
with the following monitoring once a month in the next 36 weeks. Total period of observation 
is one year (48 weeks). Detailed classes description is in the Appendix 1. 
Patients from control group do not take part in the group classes but their indicators are 
collected during the routine visits to doctors (a doctor will invite a patients following the plan 
of visits, table 7-2). 
All prescribed procedures assigned by the doctors should meet the medical needs of the 
patients and should be conducted according to the recommendations of the Russia Association 
of Endocrinologists. 
The specialists will use their professional skills in order to achieve the purposes and 
outcomes and they are responsible for taking into account the guidelines of the RAE. 
Recommendations of the nutrition specialist should be within the framework specified by 
the Russian algorithms for the patients with type 2 DM (6th edition, 2013, chapter 6.1.1. 
Recommendations for diet), namely: 
Diet therapy of the patients with type 2 DM which are overweight/obese, not receiving 
insulin 
1.1. The basic principle - moderately hypocaloric diet with the caloric deficit of 500 - 1000 
calories per day, but not less than 1500 kcal per day (men) and 1200 kcal per day (women). 
1.2. More marked caloric restriction is used only for a short time and only under medical 
supervision. Fasting is absolutely contraindicated. 
1.3. Calorie reduction is achieved by restriction of high-fat food, simple carbohydrates, as 
well as restriction of complex carbohydrates and protein by about fifty percent of the usual 
patient consumption. More strict carbohydrate restriction is not indicated. 

Novartis 
Confidential 
Page 20 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
1.4. It is not necessary to calculate the carbohydrates using carbohydrate units. 
• 
Inclusion in the diet the food products enriched with plant fiber (fiber) (vegetables and 
herbs, cereals, flour, products of household flour), unsaturated fatty acids (vegetable oils in 
small quantities, fish); 
• 
Moderate use of the noncaloric artificial sweeteners is admissible; 
• 
Use of alcoholic beverages should be not more than 1 conventional unit per day for 
women and 2 conventional units for men,* in case of the absence of pancreatitis, severe 
neuropathy, hypertriglyceridemia, alcohol dependence. 
• 
It is not recommended: 
- Intake of vitamins (in case of the absence of clinical signs of vitamin deficiency) and 
antioxidants due to the insufficient knowledge of the long-term results of their use. 
 
Recommendations of TE doctor/fitness instructor should be located within the framework 
provided by the Russian algorithms (6th edition, 2013, chapter 6.1.2. Recommendations on 
Physical Activity), namely: 
• 
Regular physical activity (PhA) in type 2 DM improves the glycemic control, helps to 
reduce and maintain the body weight, reduces the degree of insulin resistance and abdominal 
obesity, facilitating the reduction of hypertriglyceridemia, and increase in cardiovascular 
fitness. 
• 
PhA is selected individually, taking into account the patient's age, complications of 
type 2 DM, concomitant diseases, as well as the tolerability. 
• 
The aerobic exercises with duration of 30-60 min are recommended, preferably daily, 
but at least 3 times a week. The total duration is at least 150 min per week. 
• 
Contraindications and precautions for use are in general the same as for PhA and type 
1 DM (see. Section 5.1.4. Recommendations), and are defined by DM complications and 
comorbidities. 
• 
Additional factors limiting PhA in case of type 2 DM: coronary artery disease (CAD), 
diseases of the respiratory system, joints and others. 
• 
The CAD risk requires mandatory electrocardiography (ECG) (according to the 
indications - stress tests, etc.) before starting PhA study. 
In patients with type 2 DM, receiving insulin or oral hypoglycemic agents stimulating the 
insulin secretion (and very rarely - other hypoglycemic agents) PhA can cause hypoglycemia. 
 
Education and self-control are carried out with the assistance of the clinical psychologist 
should be in compliance with the principles provided in the Russian algorithms (6th edition, 
2013, Chapter 7, Education of the patients with DM). 

Novartis 
Confidential 
Page 21 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
Observation period is 12 months. The objective is to reduce weight no less than 5% compared 
with the baseline in the first three months and then to maintain the positive dynamics in the 
next 9 months. 
Weight reduction will help to improve the metabolism of carbohydrates and lipids as well as 
to reduce the risk of complications. 
10.1 
Withdrawal of Consent form 
Patients may voluntarily withdraw consent to participate in the study for any reason at any 
time.  
Withdrawal of consent occurs only when a patient does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further 
study related contacts and does not allow analysis of already obtained biologic material.  
The patient form active group will be considered as terminated the study provided he/she 
missed three group classes in a row in the first 12 weeks. 
10.1.1 Early study termination 
The study can be terminated at any time, for any reason, by Novartis. The investigator will be 
responsible for informing the Local Ethics Committee (LEC) of the early termination of the 
trial. 
10.2 
Information to be collected on screening failures 
All patients who have signed informed consent but not entered into the next epoch will have 
the study completion page for the screening epoch, demographics, inclusion/exclusion, and 
serious adverse event (SAE) data collected. Adverse events that are not SAEs will be 
followed by the investigator and collected only in the source data. 
10.3 
Patient demographics/other baseline characteristics 
All Baseline assessments should be performed prior to first study treatment administration. 
Patient demographic data to be collected on all patients include: date of birth, sex, race, 
ethnicity, and child-bearing potential (for females only), see the comments to the table 7-1. 
10.4 
Safety  
Safety assessments will be performed as indicated in Table 6-1 and Table 6-2 and will be 
based on: 
•
Evaluation of all AEs and SAEs
•
Physical examination, vital signs
•
Laboratory tests analysis
•
ECG results

Novartis 
Confidential 
Page 22 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
10.4.1 Physical examination 
A physical examination, including general appearance, will be performed as indicated in 
Table 7-1 and Table 7-2. 
If indicated, based on medical history and/or symptoms, additional exams will be performed 
at the discretion of the investigator. Information for all physical examinations must be 
included in the source documentation at the study site.  
10.4.2 Vital signs 
Vital signs (including blood pressure and pulse measurements) will be assessed as indicated in 
Table 7-1 and Table 7-2. 
DBP and SBP are measured after the patient has been sitting for 5 minutes, with their back 
supported and both feet placed on the floor, systolic and diastolic blood pressure will be 
measured twice, 1-2 minutes apart, using a validated device, with an appropriately sized cuff. 
In the event that a sufficiently large cuff is not available, a sphygmomanometer with an 
appropriately sized cuff may be used. The average of the two measurements will be entered 
into the eCRF. 
Normal blood pressure will be defined as a systolic pressure of 90 to <120 mmHg, and a 
diastolic blood pressure of 60 to <80 mmHg under the measurement conditions outlined 
above. Notable blood pressure will be hypertension (systolic blood pressure of ≥140 mmHg 
and/or diastolic blood pressure of ≥90 mmHg) or hypotension (systolic blood pressure of <90 
mmHg and/or a diastolic blood pressure of <60 mmHg).  
A normal pulse rate will be defined as a rate of 60 to 100 beats per minute (bpm) under the 
measurement conditions outlined above. Notable pulse rates are a rate below 60 bpm 
(bradycardia) or above 100 bpm (tachycardia). 
Whether action needs to be taken to address notable vital signs will be decided by the 
investigator, taking into account the overall status of the patient. No specific action is foreseen 
as part of the study protocol. 
10.4.3 
Height, weight, body mass index, waist circumference, waist/hip 
ratio  
Height, body weight, body mass index, waist circumference, waist/hip ratio will be measured 
as indicated in Table 7-1 and Table 7-2. All parameters will be measured in indoor clothing, 
but without shoes. If possible, body weight assessments should be performed by the same 
study site staff member and using the same scale throughout the study. 

Novartis 
Confidential 
Page 23 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
10.4.4 
Laboratory evaluations  
A local laboratory will be used for analysis of all specimens unless noted otherwise. 
10.4.4.1 General blood test 
All indicators will be measured at planned visits according the Table 7-1 and Table 7-2. 
10.4.4.2 Clinical blood chemistry 
All indicators will be measured at planned visits according the Table 7-1 and Table 7-2. 
10.4.4.3 Urinalysis 
All indicators will be measured at planned visits according the Table 7-1 and Table 7-2. 
10.4.4.4 Glycosylated hemoglobin 
Glycosylated hemoglobin (HbA1c) assessment should be done at visit 1 and then after 12, 24, 
36 and 48 weeks after the patient is included in the study, see Table 7-1 and Table 7-2. 
10.4.4.5 Electrocardiogram (ECG) 
A standard 12-lead ECG will be performed at visits according Table 7-1 and Table 7-2. At 
each visit when an ECG is done, the investigator must review, date and initial the tracing. The 
tracing must then be stored with the patient's source documents. 
10.4.5 
Appropriateness of safety measurements 
The safety measures used in this study are reliable and relevant standard measures for patients 
with T2DM. 
10.5 
Other assessments 
These include: 
•
Health economic supply form
•
Survey on hypoglycemia
10.5.1 
Health economic supply form 
Special designed health economic (HE) supply form should be completed by investigator at 
the visits according Table 7-1 and Table 7-2. 
This form includes the following aspects: 
•
Medical services for diabetes and it’s complications over the last year
•
T2DM drug therapy over the last year

Novartis 
Confidential 
Page 24 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
•
Related diseases drug therapy over the last year
Based on data from HE supply form health economic aspects will be analyzed. This analysis 
will be conducted separately after the final study report is completed. 
10.5.2 
Hypoglycemia Perspectives Questionnaire 
The impact of T2DM on various aspects of patient’s health-related quality of life will be 
assessed by the following validated instruments, each of which will be performed as indicated 
in Table 7-1 and Table 7-2. 
• Health Questionnaire EQ-5D-3L
• Hypoglycemia Perspectives Questionnaire
• DTSQ
Doctor (investigator or acting as investigator) should fill out this survey based on what the 
patient says. The survey will be filled out in Russian before the patient attends the 1st visit of 
the study. The doctor should ask the patient to answer the questions and fill out the survey. 
The originals should be kept with other primary documents in the research center. 
The patient should fill out the Diary of self-control in between the visits. The diary has teared-
off pages where all data on food intake, the level of glucose before and 2 hours after the food 
intake and hypoglycemia therapy should be mentioned. Additionally, the patient should 
register in the Diary the change in glucose level, BP and pulse before and after physical 
exercises. Completed pages should be given to the doctor by the patient at each visit. In case 
of AEs or SAEs they should be registered according to the instructions of the Chapter 11. 
Reporting system is also described in Chapter 11. 
11 
Safety monitoring 
Any serious adverse events will be reported to the Local Ethics Committee within 24 hours of 
the occurrence.  All serious adverse events will also be reported to Novartis Drug Safety & 
Epidemiology (DS&E) within 24 hours of the investigator (or designee) being aware of the 
serious adverse event. Specific definitions of adverse events, and serious adverse events, are 
outlined below, along with reporting criteria required by Novartis.  
Adverse events (AE) 
Information about all AEs, whether volunteered by the patient, discovered by investigator 
questioning, or detected through physical examination, laboratory test or other means, will be 
collected and recorded on an Adverse Event Case Report Form and will be followed up as 
appropriate.   
An AE is any undesirable sign, symptom or medical condition occurring after starting study 
treatment, even if the event is not considered to be part of lifestyle changes implied by this 
study.  
Medical conditions/diseases present before starting study treatment will only be considered 
adverse events if they worsen after starting study treatment (any procedures specified in the 

Novartis 
Confidential 
Page 25 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
protocol). Adverse events (but not serious adverse events) occurring before starting study 
treatment but after signing the informed consent form will be recorded on the Medical 
History/Current Medical Conditions Case Report Form. Abnormal laboratory values or test 
results constitute adverse events only if they induce clinical signs or symptoms, are 
considered clinically significant or require therapy, and are recorded on the Adverse Events 
Case Report Form under the signs, symptoms or diagnosis associated with them. 
As far as possible, each adverse event will also be described by: 
1. the severity grade (mild, moderate, severe)
2. its relationship to the drug(s) of interest (suspected/not suspected)
3. its duration (start and end dates or if continuing at final exam)
4. whether it constitutes a serious adverse event (SAE)
Serious Adverse Events (SAEs) 
Information about all serious adverse events will be collected and recorded on the Serious 
Adverse Event Report Form. To ensure patient safety each serious adverse event will also be 
reported to Novartis DS&E within 24 hours of the investigator learning of its occurrence.  
An SAE is defined as an event which: 
•
Is fatal or life-threatening
•
Results in persistent or significant disability/incapacity
•
Constitutes a congenital anomaly/birth defect
•
Requires inpatient hospitalization or prolongation of existing hospitalization, unless
hospitalization is for:
•
Routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition (specify what this includes)
•
Elective or pre-planned treatment for a pre-existing condition that is unrelated to the
indication under study and has not worsened since the start of the drug of interest
•
Social reasons and respite care in the absence of any deterioration in the patient’s
general condition
•
Is medically significant, i.e., defined as an event that jeopardizes the patient or may
require medical or surgical intervention to prevent one of the outcomes listed above e.g.
may require treatment on an emergency outpatient basis for an event not fulfilling any of
the definitions of a SAE given above and not resulting in hospital admission
•
Transmission of infectious agent via medicinal product
No specific  SAEs exempt from this reporting process are planned in this protocol. 

Novartis 
Confidential 
Page 26 
Clinical Trial Protocol v 4.0 
Protocol No. CLAF237ARU05 
Any SAE occurring after the patient has provided informed consent and until 4 weeks after 
the patient has stopped study participation will be reported. Serious adverse events occurring 
more than 4 weeks after study discontinuation will be reported to Novartis DS&E only if a 
relationship with any Novartis  study therapy is suspected by the investigator.  
Local Department of Pharmacovigilance (Clinical Safety) of Novartis Pharma in Russia 
Phone:  
 
 
 
Fax: 
 
 
 
Email:  
 
 
Specialists in drug safety: 
 
As far as possible, each SAE will also be described by (but not limited to): 
o
Its duration (onset date = date of 1st signs or symptoms, and end dates)
o
The seriousness criteria and severity if applicable (mild, moderate, severe)
o
Its relationship to current investigational regimen (suspected / not suspected as judged
by the investigator)
o
The action(s) taken and investigation results if applicable
o
Concomitant medication details
o
Outcome
Notification of serious adverse events to Novartis Pharmaceuticals Drug Safety & 
Epidemiology (DS&E) 
Each Serious Adverse Event (SAE) will be reported by the investigator to Novartis DS&E 
within 24 hours of learning of its occurrence, even if it is not felt to be related to study 
procedures or Noivartis treatment. Follow-up information about a previously reported SAE 
will also be reported to Novartis DS&E within 24 hours of receiving it. If the SAE has not 
been previously documented (new occurrence) and it is thought to be related to study 
treatment, Novartis Drug Safety Department may contact the investigator to obtain further 
information.  
If warranted, an Investigator Notification may be issued, to inform all investigators involved 
in any study with the same drug that this serious adverse event has been reported. 
Reporting procedures 
The investigator will complete the SAE Report Form, assess the relationship to study 
treatment\study procedures and send the completed and signed form by fax within 24 hours to 
Novartis DS&E. The original and the duplicate copies of the SAE Form, and the fax 
confirmation sheet will be kept with the case report forms at the study site.  

Novartis 
Confidential 
Page 27 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Follow-up information will be sent to the same person to whom the original SAE Form was 
sent, re-stating the date of the original report. A new SAE Form will be used (stating that this 
is a “follow-up”). The follow-up report should describe whether the event has resolved or 
continues, if and how it was treated, and whether the patient continued or discontinued study 
participation. The form and fax confirmation sheet will be retained by the study site. 
 
It is necessary to use a new form for SAEs reporting (it will be indicated there that new data is 
presented). While new form is presented it is necessary to report whether the previos case was 
resolved, treatment conducted or the SAEs is still ongoing. This form and fax copy will be 
kept in the research center. 
 
Reporting about pregnancy 
To ensure patient safety, each pregnancy in a patient will be reported to Novartis within 24 
hours of learning of its occurrence. Pregnancy will be recorded on a Clinical Trial Pregnancy 
Form and reported by the investigator to the local Novartis Drug Safety and Epidemiology 
Department. Pregnancy follow-up will be recorded on the same form and will include an 
assessment of the possible relationship to the Novartis study drug of any pregnancy outcome. 
Any SAE experienced during pregnancy will be reported on the SAE Report Form. 
 
12 
Data review and database management  
12.1 
Site monitoring 
Before study initiation at a site initiation visit or at an investigator meeting, a Novartis 
representative will review the protocol and eCRF with the investigators and their staff. During 
the study, the field monitor will visit the site regularly to check the completeness of patient 
records, the accuracy of entries on the eCRF, the adherence to the protocol and to Good 
Clinical Practice (GCP), the progress of enrollment. Key study personnel must be available to 
assist the field monitor during these visits. 
The investigator/qualified site staff must maintain source documents for each patient in the 
study, consisting of, but not limited to, case and visit notes (hospital or clinic medical records) 
containing demographic and medical information, laboratory data, ECGs, and the results of 
any other tests or assessments. All information on eCRF must be traceable to these source 
documents in the patient’s file. The investigator must also keep the original informed consent 
form signed by the patient (a dated and signed copy is given to the patient). 
The investigator/qualified site staff must give the monitor access to all relevant source 
documents to confirm their consistency with eCRF entries. Novartis monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all 
primary variables. Additional checks of the consistency of the source data with the eCRF are 
performed according to the study-specific monitoring plan. No information in source 
documents about the identity of the patients will be disclosed. 

Novartis 
Confidential 
Page 28 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
12.2 
Data collection  
Designated investigator staff will enter the data required by the protocol into the EDC system. 
Designated investigator site staff will not be given access to the EDC system until they have 
been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The investigator must certify that 
the data entered into the eCRF are complete and accurate. 
After database lock, the investigator/qualified site staff will receive copies of the patient data 
for archiving at the investigational site. 
12.3 
Database management and quality control  
Novartis staff, or CRO working on behalf of Novartis, review the data entered into the eCRF 
by investigational staff for completeness and accuracy and instruct the site personnel to make 
any required corrections or additions. 
Queries are sent to the investigational site using an electronic data query. Designated 
investigator site staff is required to respond to the query and confirm or correct the data. 
Concomitant medications entered into the database will be coded using the World health 
Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic 
Chemical classification system. 
Medical history and AEs will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) terminology. 
 
13 
Data analysis  
Descriptive statistics will be applied in the study to describe the sample size of the patients at 
baseline and at follow-up visits, demographic data recorded during the examination of the 
study parameters, as well as their changes. 
The choice of parametric or non-parametric criteria for testing statistical hypotheses will be 
determined on the basis of the Kolmogorov-Smirnov criteria (conclusion of the presence or 
absence of statistically significant differences between the distribution of the respective 
parameter and the normal one), as well as with the graphical methods. 
AE data will be presented as an absolute number and as the proportion of the patients with 
any AE, according to the organ systems and specific AE with corresponding 95% confidence 
intervals (CI). The association between therapy duration and AE (SAE) risk will be analyzed 
on the base of the proportional-hazards regression model of the survival analysis. Age, sex, 
BMI, disease duration, baseline HbA1c. will be taken into account in the model for the control 
of potential confounding factors. Secondary indicators will be analyzed the same way. 
The primary analysis of the proportion of the patients with response on the treatment will be 
performed using multivariate logistic regression and calculating odds ratios with 

Novartis 
Confidential 
Page 29 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
corresponding 95% CI. To control the potential confounding factors, age, sex, BMI, disease 
duration, the baseline values of HbA1c will be taken into account in the regression model. 
The Last observation carried forward method (LOCF) will be used to restore the missing 
values of the efficacy indicators at the final visit according to the last available measurement 
after initiation of studied intervention. Sample size calculation 
13.1 
Sample size calculations 
The primary objective of this study is to assess the change of weight from baseline, in patients 
with T2DM at 12 months in comparison to the change in weight from baseline in the parallel 
cohort. Sample size is calculated based on observed weight changes in Why Wait study 
conducted at the Joslin center. The average weight loss observed at the end of 12 months was 
8%. Given that baseline criteria and translation of the program can be different in executing 
this in Russia, we have assumed an achievable change in weight as 5%. The sample size (with 
the possible dropout of 20% ) of 100 patients in active group and 30 patients in parallel cohort 
is required to provide 80% power to detect a significant difference (significance level is 
α=0.05) between values in two groups.  
 
14 
Ethical considerations 
14.1 
Council of Ethics 
The study can be started only after written approval of Local Ethic Committee, which is in 
accordance with the international quidelines on Good Clinical Practice and with federal 
legislation. 
14.2 
Ethical support of the study 
An investigator and all subjects and organizations involved in the study should conduct the 
present study in compliance with the Protocol, GCP standards. 
The confidentiality of the records identifying the subject of the study should be ensured in 
compliance with the right on the private life and protection of the data confidentiality 
according to the normative requirements. 
The rights, safety and welfare of the subject of the study are of a high priority and should be 
prevail over the interests of the science and society. 
14.3 
Patient Informed Consent 
The Investigator and co-investigator, using the printing materials, should explain to the patient 
the purposes and the scope of the study, as well as the other issues related to the study and it 
should  be clear, that the presented information has been completely recognized by the patient 
and the written consent on participation in the study has been the free expression of patient’s 
will. 

Novartis 
Confidential 
Page 30 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Before the onset of the participation of the study the patient or his/her legal representative, 
made the expository conversation, personally sign and put the date on the written Informed 
Consent Form. 
Investigator or other responsible personnel should handle directly to the patient the copy of 
the Informed Consent, an original copy of which will be archived by an investigator in 
accordance with the rules of Good Clinical Practice. 
The Information card and Consent form for patients in active and control groups will be 
different according to the plan of visits for these groups. 
The signed Informed Consent Form should be stored by the Investigator and be available 
(only for review) for the specialists on Clinical Monitoring and for an auditor, if required. 
14.4 
Confidentiality of the personal data of the patients 
Personal clinical information, obtained in the course of the present study is considered as 
confidential and should not be disclosed to the third parties. Investigator must ensure the 
adherence to the anonymity of the patients and protection of this data, disclosing the patient 
personality, from the subjects not authorized to receive assess to this information. Data of the 
patient received by the Sponsor and/or by the Contract Research Organization, involved in the 
study conduction, can include only identification number of the patient and/or his/her initials. 
Initials of the sponsor confirms that the personal data of the patients will be protected with the 
complete compliance with the requirements of the Federal Law No. 152-FZ from July 27, 
2006 “On the Personal Data”. 
 
14.5 
Regulatory and ethical compliance  
This clinical study was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations and with the ethical principles laid down in the Declaration of Helsinki. 
14.6 
Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC-approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative(s) of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study to the extent possible given his/her understanding. Only those 
patients will be included in the study who understand all study related procedures and their 
obligations to complete the study. Informed consent must be obtained before conducting any 
study-specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents.  
Novartis will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory requirements and is 
considered appropriate for this study. Any changes to the proposed consent form suggested by 

Novartis 
Confidential 
Page 31 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
the investigator must be agreed to by Novartis before submission to the IRB/IEC, and a copy 
of the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
14.7 
Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution should obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g., advertisements) and any other written information to be provided to patients. 
Prior to study start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory authorities as required. If an inspection of the 
clinical site is requested by a regulatory authority, the investigator must inform Novartis 
immediately that this request has been made. 
14.8 
Publication of study protocol and results  
Novartis assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for publication 
and/or posted in a publicly accessible database of clinical trial results. 
15 
Protocol adherence 
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
trial to request approval of a protocol deviation, as requests to approve deviations will not be 
granted. 
This protocol defines the study objectives, the study procedures and the data to be collected 
on study participants. Under no circumstances should an investigator collect additional data or 
conduct any additional procedures for any research-related purpose involving any 
investigational drugs. 
If the investigator feels a protocol deviation would improve the conduct of the study, this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the clinical study report (CSR). 
16 
Protocol Amendments  
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation. Only amendments that are intended to eliminate an apparent immediate 
hazard to patients may be implemented immediately provided the Health Authorities are 
subsequently notified by protocol amendment and the reviewing IRB/IEC is notified. 

Novartis 
Confidential 
Page 32 
Clinical Trial Protocol v 4.0  
 
Protocol No. CLAF237ARU05 
 
 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any patient included in this 
study, even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in section 7 Safety Monitoring should be followed. 
17 
References  
1. Zimmet, Alberti, Shaw, 2001 
2. Hill JO, Wyatt H, Outpatient management of obesity: a primary care perspective, Obes 
Res, 2002; 10(Suppl. 2):124S–130S, YU AP et al. Curr Med Res Opin. 
2007;23(9):2157-69 
3. Hubert H.B., Feinleib M., McNamara P.T., Castell W.P. Obesity as an independent 
risk factor for cardiovascular disease: a 26–year follow–up of participants of the 
Framingham Heart Study. Circulation 1983; 67: 968–977 
4. Dedov I.I., Melnichenko G.A., Romantsova T.I. Patogenetic aspects of obesity. 
Ovesity and metabolism. 2004; 1: 3-9. 
5. Look Ahead Research Group. Arch Intern Med. 2010;170(17):1566–1575 
6. The algorythms of the specialised medical care for the patiens with diabetes mellitus, 
6th ediction, under the editorship of I.I. Dedov, M.V. Shestakova, Moscow, 2013.